0

β-lapachone and α-nor-lapachone Modulate Candida Albicans Viability and Virulence Factors

D C Moraes, J A R Curvelo, C A Anjos, K C G Moura, M C F R Pinto, M B Portela, R M A Soares

J Mycol Med. 2018 Jun;28(2):314-319.

PMID: 29598974

Abstract:

Background:
Candida albicans is the most important fungal pathogen that causes infections in humans, and the search for new therapeutic strategies for its treatment is essential.
Objective:
The aim of this study was to evaluate the activity of seven naphthoquinones (β-lapachone, β-nor-lapachone, bromide-β-lapachone, hydroxy-β-lapachone, α-lapachone, α-nor-lapachone and α-xyloidone) on the growth of a fluconazole-resistant C. albicans oral clinical isolate and the effects of these compounds on the viability of mammalian cells, on yeast's morphogenesis, biofilm formation and cell wall mannoproteins availability.
Results:
All the compounds were able to completely inhibit the yeast growth. β-lapachone and α-nor-lapachone were the less cytotoxic compounds against L929 and RAW 264.7 cells. At IC50, β-lapachone inhibited morphogenesis in 92%, while the treatment of yeast cells with α-nor-lapachone decreased yeast-to-hyphae transition in 42%. At 50μg/ml, β-lapachone inhibited biofilm formation by 84%, whereas α-nor-lapachone reduced biofilm formation by 64%. The treatment of yeast cells with β-lapachone decreased cell wall mannoproteins availability in 28.5%, while α-nor-lapachone was not able to interfere on this virulence factor. Taken together, data show that β-lapachone and α-nor-lapachone exhibited in vitro cytotoxicity against a fluconazole-resistant C. albicans strain, thus demonstrating to be promising candidates to be used in the treatment of infections caused by this fungus.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP4707328 β-Lapachone β-Lapachone 4707-32-8 Price
qrcode